TXG logo

10X GENOMICS INC-CLASS A

TXGNASDAQ
πŸ† #752 by market capEarnings Nov 5 Β· PostUS Equity
$83.55β–² $5.54 (+7.10%)
After hours Β· at close
πŸ””
Track TXG
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.1%
7dβ–² 10.7%
14dβ–² 14.2%
30dβ–Ό 5.6%
ytdβ–² 412.3%
1yβ–² 525.8%
🏦Market Cap
$10.89B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-4.3%
Declining
πŸ“ŠGross Margin
69.6%
High
πŸ’΅FCF Margin
19.7%
Healthy
βš–οΈP/S Ratio
16.6x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$78.62 – $87.72
52-Week Range
$12.34 – $102.81
Volume (shares)
406,533
Avg Volume (shares)
β€”
Shares Outstanding
130.3M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$643M
Last Q Revenue
$151M
P/E Ratio
β€”
P/S Ratio
16.6x
EPS (TTM)
$-0.59
Dividend Yield
β€”
Dilution (1yr)
+4.5%
TXG logo

10X GENOMICS INC-CLASS A

TXG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$643Mβ–² +5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
69.1%β–² +1.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$111Mβ–Ό βˆ’43.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$130Mβ–Ό βˆ’2371.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
127.1Mβ–² +4.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$316Mβ–² +$55M YoY
StockOtter Β· stockotter.space

About 10X GENOMICS INC-CLASS A

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Ratings

β“˜
Consensus
Buy
22 analysts
Strong Buy6
Buy4
Hold12
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.